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Abstract
Purpose 131I- and 90Y-labelled anti-CD20 antibodies have
been shown to be effective in the treatment of low-grade,
B-cell non-Hodgkin’s lymphoma (NHL). However, the
most appropriate radionuclide in terms of high efficiency
and low toxicity has not yet been established. In this
study we evaluated an immunoconjugate formed by the
anti-CD20 antibody rituximab and the chelator DOTA
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid).
DOTA-rituximab was prepared as a kit formulation and
can be labelled in a short time (<20 min) with either
177Lu or 90Y.
Materials and methods Immunoconjugates with different
numbers of DOTA molecules per rituximab were prepared
using p-SCN-Bz-DOTA. In vitro immunoreactivity and
stability were tested and preliminary dosimetric results were
acquired in two patients.
Results The immunological binding properties of DOTA-
rituximab to the CD20 antigen were found to be retained
after conjugation with up to four chelators. The labelled
product was stable against a 105 times excess of dieth-
ylenetriaminepentaacetic acid (DTPA, 37°C, 7 days). Two
patients with relapsed NHL were treated with 740 MBq/m2
body surface 177Lu-DOTA-rituximab. Scintigraphic images
showed specific uptake at tumour sites and acceptable
dosimetric results. The mean whole-body dose was found
to be 314 mGy. The administration of 177Lu-DOTA-
rituximab was tolerated well.
Conclusion Our results show that DOTA-rituximab (4:1)
can be labelled with 177Lu with sufficient stability while the
immunoconjugate retains its immunoreactivity. 177Lu-
DOTA-rituximab is an interesting, well-tolerated radio-
labelled antibody with clinical activity in a low dose range,
and provides an approach to the efficient treatment with
few side effects for patients with relapsed NHL.
Keywords 177Lu-DOTA-rituximab . Non-Hodgkin’s
lymphoma . Radioimmunotherapy . CD20+ lymphoma
Introduction
The monoclonal antibody rituximab has become a standard
treatment for relapsed or refractory CD20-positive low-grade
non-Hodgkin’s lymphoma (NHL), along with chemotherapy
[1]. Rituximab is a chimeric antibody, discovered in 1990 by
IDEC Pharmaceuticals (San Diego, CA). It possesses a high
binding affinity to the CD20 antigen. The CD20 antigen is
expressed on the surface of normal and malignant B-
lymphocytes but not on stem cells or other healthy tissues.
Rituximab kills CD20-positive B-lymphocytes via a mech-
anism involving antibody-dependent cytotoxicity [2, 3].
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Moreover, a mechanism such as apoptosis, which is
independent of complement or antibody-dependent cytotox-
icity, may also be triggered by cell surface coupling and
then play a role in the tumoricidal effect [4].
Over recent years, radioimmunotherapy has been used in
the treatment of CD20+ lymphomas. Mostly low-grade
NHL that has relapsed or that is refractory to the last
standard therapy is treated. Radioimmunotherapy is used
alone or in combination with other therapies with the goal
of improving efficacy [5–7]. For this purpose beta-emitting
radioisotopes are coupled to anti-CD20 antibodies. Lym-
phocytes and lymphoma cells are highly radiosensitive.
Additionally, due to the millimetre-range of β-particles, the
so-called “cross-fire” effect (in internal radiotherapy)
allows cells devoid of radioactive-bound antibody to be
irradiated and killed [8]. This is particularly relevant to
lymphoma cells which lack antigens, or which cannot be
reached due to poor vascularization and intratumoral
pressure in a bulky tumour.
Radioimmunotherapy using anti-CD20 antibodies la-
belled with 131I is a promising approach to the treatment
of low-grade NHL [3]. A pilot study in 53 patients showed
an overall response rate of 71%, including 38% of patients
with complete remission and a median progression-free
survival of 12 months (20.3 months for the complete
responders) [9, 10]. Another, highly regarded study using
radioimmunotherapy as first-line treatment for follicular
lymphoma showed complete remission in 75% of all
patients [11].
The pure, high-energy, β-emitting isotope, 90Y is also
used in radioimmunotherapy in relapsed NHL patients. For
the preparation of the commercially available Zevalin
(IDEC Pharmaceuticals, San Diego, CA), the murine form
of rituximab (ibritumomab) is labelled with 90Y. However,
90Y-Zevalin is not suitable for dosimetry [12–14]. The use
of 111In as a surrogate for 90Y is necessary for prether-
apeutic dosimetry. Moreover, 90Y delivers more energy to
the tumour which might be advantageous in big tumours,
but for micrometastases and consolidation therapy the
energy is probably too high, resulting in the highest energy
being absorbed outside the tumour. Thus, the combination
of a high- and a low-energy β-emitting isotope, e.g. 131I
and 90Y, as an “isotope cocktail” for the labelling of an anti-
CD20 antibody might induce even higher rates of response
and longer lasting responses in NHL patients who have
failed to respond to treatment with chemotherapy, rituximab
or a combination.
However, 131I is not an ideal radioisotope for use in the
clinic. It has the disadvantage of a high rate of emission of
γ-radiation (364 keV, 82%; 637 keV, 7%). For instance,
with respect to the European radiation protection law, this
would result in prolonged hospitalization. Additionally, this
may lead potentially to high radiation absorbed doses to
staff and the family of the patient. Another inevitable
drawback is the in vivo deiodination of antibodies [15]. A
radiometal such as 177Lu (Emax 0.497 MeV, t½ 6.7 days)
may be more suitable for the labelling of the antibody.
Beside its β-emission, it features a low abundance of
photons of almost ideal energy (113 keV, 6.5%; 208 keV,
11%) for imaging and posttherapeutic dosimetry.
In this study, we set out to attach an appropriate multiple
number of DOTA molecules to rituximab and produce a
reliable lyophilized kit formulation that would allow the
rapid labelling of the antibody in a routine laboratory. We
analysed the labelling efficiency of DOTA-rituximab with
177Lu and 90Y as well as the immunoreactivity before and
after conjugation and labelling, respectively. The conjuga-
tion and labelling conditions were optimized to ensure that
the final product could be obtained in high yield without
loss of biological activity. Additionally, a dosimetric study
in two patients with relapsed lymphoma treated with 177Lu-
DOTA-rituximab was performed.
Materials and methods
Materials
Chimeric anti-CD20 rituximab monoclonal antibodies were
provided by Roche (Roche Pharma Schweiz, Basel,
Switzerland). 57Co was purchased from Amersham Biosci-
ence (Piscataway, NJ). 177Lu was purchased either from I.
D.B. Holland (Baarle Nassau, The Netherlands) or from
MURR (University of Missouri Research Reactor, Colum-
bia, MO). 90Y was purchased from PerkinElmer Life
Sciences (Waltham, MA). Isothiocyanate-benzyl-DOTA
(p-SCN-Bz-DOTA) was purchased from Macrocyclics
(Dallas, TX). All chemicals were purchased from commer-
cial sources and used without additional purification.
Cells
L-VB1 is a mouse fibroblast cell line transfected with the
human CD20 cDNA, which was kindly provided by Dr. H.
Kikutani (Osaka University, Japan). The cells were grown
in RPMI-1640 medium supplemented with 2 mM L-
glutamine and 10% heat-inactivated fetal calf serum
(FCS). Prior to use, the cells were detached from the
surface of the tissue culture flask by treatment with trypsin
(0.05%) in PBS with EDTA (0.02%), and counted.
Antibody conjugation and kit formulation
A 5-ml aliquot of rituximab solution (10 mg/ml) was
concentrated by centrifugation using an Amicon Ultra-15
filter (Millipore, MWCO 30,000). The solution was washed
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three times with 0.2 M sodium carbonate buffer (coupling
buffer), pH 9.5, to remove Tween-80 and sodium citrate
and to exchange buffer. The final concentration was
100 mg/ml. The rituximab was then incubated with p-
SCN-Bz-DOTA at 37°C for 1 h in molar ratios of 1:5 or
1:20. The coupling reaction was quenched by adjusting the
pH to 7.0 using 0.25 M ammonium acetate buffer, pH 5.5,
followed by centrifugation. The solution was then washed
three to five times with 0.25 M ammonium acetate, pH 7.0;
filtration and washing was continued until the volume of
filtered solution was close to zero while the filtrate was
monitored by UV spectrophotometry (Perkin Elmer Lamb-
da2 UV/Vis spectrophotometer) at 280 nm. The concentra-
tion of rituximab was determined spectrophotometrically at
280 nm, and the immunoconjugate was diluted with 0.25 M
ammonium acetate buffer, pH 7.0. at a concentration of
5 mg/ml.
The immunoconjugate solution (1 ml, 5 mg/ml) was
prepared in kit form by lyophilization with 250 µl of
mannitol (mannitol Ph Eur, 80 mg/ml in distilled water).
Both the immunoconjugate solution and the mannitol
solution were filtered through sterile 0.45-µm filters
(Millipore) before lyophilization. The final product was a
white pellet.
Determination of the number of chelators per antibody
molecule
`A rituximab kit was reconstituted with 470 µl water for
injection and the final volume was considered as
approximately 500 µl, and the concentration of rituximab
was re-determined by UV spectrophotometry. 57Co was
prepared in 3×10−4 M CoCl2 (
57Co:CoCl2 1:10), and an
aqueous solution of 3×10−4 M natLuCl3 with a tracer
amount of 177LuCl3 was also prepared. Rituximab and
57Co/CoCl2 solutions (molar ratio 1:5 or 1:10), as well as
rituximab and 177Lu/natLuCl3 solutions (molar ratio 1:10)
were incubated at 37°C. After 1 h, 20 µl of labelled
solution was taken and quenched by the addition of 3 µl of
CaDTPA (1×10−4 M) in 25 µl of 0.25 M ammonium
acetate, pH 7.0. The sample was then analysed by HPLC,
using a TSK-Gel G3000SWXL size-exclusion column
7.8×300 mm, pre-equilibrated with 0.05 M phosphate
buffer, pH 6.8, at a flow rate of 1 ml/min. The column
eluent was passed through a UV detector (detection
wavelength 280 nm) and then through a radioactivity
detector. The number of chelators per antibody molecule
was determined by calculating the area under the curve,
which was measured radiometrically. The retention times
were compared with those of the unlabelled and of the
unconjugated antibody.
Matrix-assisted laser desorption ionization mass spec-
troscopy (MALDI-MS) measurements were performed
on a Voyager sSTR equipped with a Nd:YAG laser
(355 nm) (Applied BioSystems, Foster City, CA) for the
determination of the number of chelators per antibody
molecule, as an alternative to the tracer method. The
unconjugated rituximab and the reconstituted kit of the
immunoconjugate DOTA-rituximab were desalted by
centrifugation at 4°C using Ultra-15 filters, and washed
several times with milliQ water. The concentration was
adjusted to 20–25 mg/ml. The samples were deposited
directly on a metal MALDI target plate and sinapinic
acid (10 mg/ml in 50:50 acetonitrile/water with 0.1%
TFA) was used as the MALDI matrix at a sample to
matrix volume ratio of 1:1.
177Lu- and 90Y-labelling of the DOTA conjugate
177LuCl3 and
90YCl3 were used for the labelling of the
DOTA-rituximab kit. The kit was reconstituted as described
above and the designated amount of activity was added
slowly to the vial through the septum using a sterile single-
use syringe. The reaction mixture was incubated from
15 min to 4 h at 37°C. The amount of 177Lu and 90Y used
was 1,480 MBq and 925 MBq per kit, respectively, and the
volume ranged from 100 to 200 µl. The pH value of the
reaction mixture was checked before incubation. At
different time points, ranging from 15 min to 4 h,
approximately 3 µl of the labelling mixture was taken and
quenched by the addition of 5 µl of CaDTPA (1×10−4 M) in
500 µl of 0.25 M ammonium acetate buffer, pH 7.0. An
aliquot of 10–20 µl was then used for the analysis by size-
exclusion HPLC using the conditions described above.
Stability study
The stability of the radiolabelled immunoconjugate 177Lu-
DOTA-rituximab was evaluated in the presence of a
competitor for the 177Lu ions such as DTPA. For this
purpose a 105 times excess of CaDTPA (1×10−4 M, pH 7.3)
was added to the 177Lu-DOTA-rituximab solution and kept
at 37°C for 7 days. Samples of this mixture were removed
at different time points (4 h, and 1, 3, and 7 days) and were
analysed by size-exclusion HPLC as described above.
Immunoreactivity
The immunoreactivity of the DOTA-rituximab-
immunoconjugate was analysed by flow cytometry before
labelling and a binding assay was performed as described
by Lindmo et al. [16] after labelling with 177Lu.
Flow cytometry The binding of serial dilutions of DOTA-
rituximab and unconjugated rituximab to CD20 transfectant
L-VB1 cells was compared. Antibody dilutions ranging
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from 50 µg/ml to 390 ng/ml were prepared in FACS buffer
Dulbecco’s PBS (Sigma-Aldrich) with 2% FCS and 0.1%
sodium azide. Staining was performed in a 96-well micro-
titre plate (U-bottom). In each well 100 µl of the antibody
was mixed with 50 µl cell suspension containing 5×105 L-
VB1 cells and incubated for 1 h on ice. Cells were washed
twice with FACS buffer by centrifuging the plate and
siphoning off the supernatant. Subsequently, 100 µl per
well goat antihuman IgG/Fc-FITC (Jackson ImmunoRe-
search, West Grove, PA) diluted 1:100 in FACS-buffer was
added as second step reagent. The plate was incubated for
30 min on ice in the dark and cells were washed again twice
as described above. Dead cells were discriminated by
propidium iodide staining. Analysis was carried out on a
FACScan cytometer (Becton Dickinson, Heidelberg, Ger-
many) using CELLQUEST software.
Lindmo test L-VB1 cells were suspended in DMEM
medium supplemented with 1% FCS at a concentration of
3.2×105 cells/ml. Four six-well microtitre plates were used
for the study and 1.25 ml of the cell suspension (4×105
cells) was added to the first well of each plate. Serial 1:2
dilutions of the cells were added into the following five
wells of each plate. The plates were incubated at 37°C
overnight. The next day, the medium was removed and
1.25 ml of 4% paraformaldehyde in PBS was added to each
well. The plates were incubated at room temperature for
20 min to fix the cells to the bottom of the wells. The
paraformaldehyde solution was removed and the wells were
washed twice with PBS (0.01 M, pH 7.3). The plates were
additionally incubated at 37°C for 1 h with PBS supple-
mented with 2% FCS. To two of the four six-well microtitre
plates was added 0.5 ml of commercial rituximab (2 µM) in
PBS/2% FCS in order to saturate the binding sites for
subsequent measurement of the nonspecific binding of
radiolabelled antibody. 177Lu-DOTA-rituximab was diluted
in PBS/2% FCS to a concentration of 2.5 ng/ml and 0.5 ml
was added to each well of the four plates. The appropriate
amount of PBS/2% FCS was added to each well to obtain a
final volume of 1.25 ml per well. The final concentrations
were 1 ng/ml for 177Lu-DOTA-rituximab and 3.2, 1.6, 0.8,
0.4, 0.2 and 0.1×105 cells/ml. The plates were incubated at
37°C for 2 h. The solution was removed from each well,
followed by two washing steps with PBS, as described
above. The cells were digested from the wells by the
addition of 1.25 ml NaOH (1 N), followed by incubation at
37°C for 30 min. The digested cell solutions were
transferred to glass γ-counter tubes. The wells were washed
with 1.25 ml NaOH (1 N) and the wash solutions were
pooled to the corresponding tubes and measured in a γ-
counter (CobraΙΙ, Auto-Gamma, Canberra, Meriden, CT),
while 0.5 ml of 177Lu-DOTA-rituximab was measured to
determine the total applied radioactivity.
Dosimetry
Two patients were included in dosimetric studies. In accor-
dance with the accepted protocols for Zevalin® and Bexxar®,
patients were pretreated with rituximab at 250 mg/m2 body
surface on day −7 and 0. Later on day 0 they were injected
with 740 MBq/m2 177Lu-DOTA-rituximab. Whole-body
scans were obtained 1, 2, 4, 24, 48, 72, 120, 168 and
357 h and 1, 2, 4, 24, 48, 96, 144 and 313 h after injection,
respectively. Regions of interest were drawn manually
around the whole body from the anterior and posterior
projections. The Odyssey XP program was used. Back-
ground regions were placed close to the whole body for
background correction. The geometric mean value of the
counts from the anterior and posterior projections was taken
and corrected for physical decay. Whole-body activity
acquired 1 h after injection was defined as 100% of the
injected activity (%IA). The patients did not void their
bladder during this period. All data are expressed as %IA(t).
The resulting time–activity data from the scans were fitted by
a one-exponential curve. The activity in blood was fitted by a
three-exponential curve. The residence times were deter-
mined by using these data and the half-life of 177Lu.
According to ICRP 23, the residence time for red marrow
is 2% of the whole-body residence time, assuming that only
the blood pool contributes to the total body activity [17, 18].
We assumed no specific uptake in the red marrow. Both
patients had less than 20% infiltration of the bone marrow.
The whole-body dose and the dose to the red marrow were
calculated with the dose factors (S-values) published on
www.doseinfo-radar.com.
Results
Multiple DOTA molecules on rituximab
For the preparation of the immunoconjugate, initially
rituximab (10 mg/ml in 0.2 M sodium carbonate buffer,
pH 9.0) was incubated for 2 h with a five- to tenfold excess
of p-SCN-Bz-DOTA, resulting in a DOTA-rituximab
conjugate with an approximate ratio of one DOTA
molecule per antibody. However, this (DOTA)1-rituximab
kit was found to be unsuitable for labelling with the desired
amount (1,480 MBq per 5-mg kit) of a radiometal, such as
177Lu. The labelling yield was less than 95% after 4 h of
incubation.
Modifying this coupling procedure by increasing the pH
value of the coupling buffer to 9.5 and increasing the
rituximab concentration (100 mg/ml) resulted in conjugation
of multiple DOTA molecules per antibody. The number of
DOTA molecules per antibody was determined by labelling
of the (DOTA)X-rituximab conjugates with
57Co/CoCl2 (1:5
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and 1:10 ratio), as well as with 177Lu/natLuCl3 (1:10 ratio).
An average of four DOTA molecules per rituximab
molecule [(DOTA)4-rituximab] was found by HPLC anal-
ysis and calculation of the area under the curve (a 1:10 ratio
of rituximab to 177/natLu resulted in 40% of 177/natLu-
DOTA-rituximab; Fig. 1). Equivalent results were found for
the 57Co/CoCl2 method.
As an alternative to the determination of the number of
DOTA molecules per rituximab molecule, MALDI-MS was
used. The results (Fig. 2) showed an average number of
four DOTA molecules per rituximab. A peak at a mass-to-
charge ratio (m/z) of 146,954 corresponded to unconjugated
rituximab, while a peak at 149,146 corresponded to
conjugated (DOTA)x-rituximab. The mass difference be-
tween conjugated and unconjugated rituximab divided by
the expected mass of single DOTA coupling (551)
represents the average number of DOTA molecules conju-
gated to rituximab. The wider peak profile of the (DOTA)x-
rituximab is a result of the heterogeneous distribution of
DOTA molecules per rituximab.
In order to evaluate the effect of the number of DOTA
molecules per antibody and the immunoreactivity of the
conjugate, we conjugated a higher number of DOTA
molecules to rituximab using the modified method and a
higher amount of p-SCN-BzDOTA (20-fold excess) during
the coupling reaction. Under these conditions a DOTA-
rituximab kit with an average number of eight DOTA
molecules per antibody [(DOTA)8-rituximab] was obtained.
Immunoreactivity of (DOTA)x-rituximab
immunoconjugates
DOTA-rituximab kits containing four or eight DOTA
molecules per antibody molecule were compared side by
side with unconjugated rituximab antibody. The binding of
both preparations to cells of the CD20-transfected cell line
L-VB1 was assessed using serial antibody dilutions
(Fig. 3). At a concentration of 5 µg/ml unconjugated
rituximab showed strong binding to the target cells (mean
fluorescence intensity, MFI, 348). With (DOTA)4-rituximab
at the same concentration a slight shift of the histogram to
Fig. 1 Multiple DOTA molecules conjugated per rituximab molecule.
An average of four DOTA molecules per rituximab was determined
by calculation of the area under the curve (a 1:10 molar ratio of
rituximab to 177/natLu resulted in 40% integration from the 1777natLu-
DOTA-rituximab; Rt=7.9 min for
177/natLu-DOTA-rituximab and
Rt=11.63 min for
177/natLu-DTPA)
Fig. 3 Immunoreactivity of (DOTA)x-rituximab conjugates. Cyto-
fluorimetric comparison of unconjugated rituximab (solid bold line),
(DOTA)4-rituximab (dotted line) and (DOTA)8-rituximab (solid thin
line). The fluorescence intensity is presented as an overlay plot for
identical antibody concentrations. The shaded histogram represents a
negative control using irrelevant polyclonal human immunoglobulin
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Fig. 2 Overlapping of MALDI-MS spectra of unconjugated rituximab
and (DOTA)4-rituximab immunoconjugates. The average number of
DOTA molecules per rituximab molecule in the (DOTA)x-rituximab
conjugate can be estimated by the mass difference between unconju-
gated rituximab (146,954) and DOTAx-rituximab immunoconjugate
(149,146) divided by the mass of single DOTA coupling (551)
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the left was observed (MFI 271), indicative of a moderate
reduction of the binding activity. In contrast, the binding
capacity of (DOTA)8-rituximab was drastically impaired as
demonstrated by a clear shift of the histogram towards the
negative control (MFI 77).
Radiolabelling with 177Lu or 90Y
The (DOTA)4-rituximab kit (5 mg per kit) was first labelled
with 177Lu. The pH of the reaction mixture was in the range
5.0 to 6.0. The reaction mixture was incubated at 37°C and
at the preselected time points of 15, 30, 45, and 60 min, an
aliquot (approximately 3 µl) was taken and analysed by
HPLC as described above. The results revealed that a
sufficient labelling yield (>99%) could be achieved within
15 min (Fig. 4). The radiolabelled antibody eluted at
7.9 min, and there was a small peak at 6.8 min (1–1.5%)
which was probably due to dimer or polymer species
formed during the conjugation reaction.
Labelling of the same (DOTA)4-rituximab kit with
90Y at
pH<7.0 was insufficient. Adjustment of the pH to within
the range 7.0–7.8 by reconstitution of the kit with 0.25 M
ammonium acetate, pH 8.8, increased the labelling yield
significantly. The labelling yield was found to be 96–97%
at 30 min and increased to >99% at 1 h.
Stability of 177Lu-DOTA-rituximab
The stability of 177Lu-DOTA-rituximab with regard to trans-
chelation was evaluated in the presence of a competitor in
excess (105-fold excess of DTPA) at 37°C over a period of
7 days. The results are presented in Fig. 5. HPLC analysis at
4 h, and 1, 3 and 7 days showed that >97% of radioactivity
was still bound to the antibody on day 7. No release of free
177Lu or 177Lu-DOTA was detected after 7 days, which
indicates the high stability of the radioimmunoconjugate.
Immunoreactivity of 177Lu-(DOTA)4-rituximab
An immunoreactivity assay described by Lindmo et al. [16]
was adopted to determine the immunoreactive fraction of
the radiolabelled rituximab. The results are presented in
Fig. 6a. The nonspecific binding was calculated by
employing unlabelled rituximab to block the binding sites
on the cell surface and this was subtracted from the total
applied activity (TA) to calculate the specific binding (SB)
of 177Lu-DOTA-rituximab to cells of the lymphoma cell
line L-VB1. Figure 6a is a plot of the ratio of specifically
bound radiolabelled antibody to the total applied radioac-
tivity (SB/TA) as a function of cell concentration. In this
plot, the plateau value of SB/TA was >0.7 for the highest
cell concentration, indicating that most of the radiolabelled
antibody retained its immunoreactivity in high percentage
(a plateau of 1.0 indicates 100% of immunoreactivity).
However, the precise value of the plateau cannot be
extracted from this plot.
A double inverse plot of [TA]/[SB] as a function of the
inverse cell concentration (1/[cells]) was designed for the
calculation of the immunoreactive fraction (Fig. 6b). Fitting
a straight line through these data allows the determination
of the intercept value at the ordinate, which equals 1/r
where r represents the immunoreactive fraction of the total
amount of antibody. Our data showed a linear relationship
between TA/SB and 1/[cells], described by the equation
Fig. 4 HPLC analysis of 177Lu-DOTA-rituximab. DOTA-rituximab
(5 mg) was labelled with either 177Lu or 90Y at 37°C. High labelling
yields (>99%) were achieved within 15 min for 177Lu at pH 6.0 to 7.0,
while a 1-h incubation period at pH 7.0 was necessary for 90Y to
achieve this high labelling yield. The HPLC profile for both radio-
labelled compounds (177Lu-DOTA-rituximab and 90Y-DOTA-rituximab)
was the same (Rt=6.8 min for dimer or polymer species, Rt=7.9 min for
177Lu-DOTA-rituximab, and Rt=11.5 min for
177Lu-DTPA)
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Fig. 5 Stability of 177Lu-DOTA-rituximab against a high excess of
DTPA. 177Lu-DOTA-rituximab was incubated with a 105 times excess
of CaDTPA (1×10−4 M, pH 7.3) at 37°C for up to 7 days. Samples of
this solution were taken at 4 h, and 1, 3 and 7 days for analysis by
gel filtration TSK-3000-HPLC. After 7 days 177Lu was found to be
still bound to DOTA-rituximab, while no free 177Lu or 177Lu-DOTA
was detected
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y = 0.066x + 1.181. The immunoreactive fraction was
found to be r = 1/1.181 = 0.847.
Dosimetry
A dosimetric study using (DOTA)4-rituximab labelled with
177Lu was performed in two patients with relapsed NHL.
Both patients were injected with 740 MBq/m2 177Lu-
DOTA-rituximab. The total dose administered was 1,480
and 1,110 MBq, respectively. The injections were well
tolerated by both patients. In both patients specific tumour
uptake was seen over time. An example scintigraphic image
acquired 4 days after injection together with the corresponding
pretherapeutic 18F-FDG-PET image are shown in Fig. 7.
Whole-body activity determined by the scintigraphic images
could be fitted monoexponentially. The effective half-lives
were 136 h and 128 h, respectively. This resulted in whole-
body doses of 351 mGy (0.24 mGy/MBq) and 277 mGy
(0.25 mGy/MBq), respectively. The doses to the red marrow
were calculated as 536 mGy (approximately 0.36 mGy/
MBq) and 425 mGy (0.38 mGy/MBq), respectively.
Discussion
Rituximab labelled with radionuclides may provide a better
therapeutic effect than rituximab alone in patients with
relapsed or refractory B-cell NHL. Macrocyclic chelator
molecules such as DOTA need to be coupled to rituximab
to enable stable labelling with radiometals. Many methods
a b axillary lymphnodes
mesenterial lymphnodes
inguinal lymphnodes 
mediastinal „bulk“ 
liver  
bladder 
Fig. 7 a Pretherapeutic 18F-
FDG-PET image (MIP data) of
a patient with grade IV follicular
lymphoma (lymph node in-
volvement above and below the
diaphragm as well as liver infil-
tration). b Planar whole-body
scintigraphic image of the same
patient (anterior view) 4 days
after injection of 40 mCi 177Lu-
DOTA-rituximab. Specific up-
take at tumour sites as well as
nonspecific accumulation of the
radiopharmaceutical in the liver
is seen
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Fig. 6 Lindmo binding assay for the determination of the immuno-
reactive fraction of 177Lu-(DOTA)4-rituximab. The assay was set up
using six concentrations of L-VB1 cells in a series of 1:2 dilutions
from 0.33 to 0.01 million cells/ml. The final concentration of 177Lu-
(DOTA)4-rituximab was 1 ng/ml. a Conventional plot of specific
binding over total applied radioactivity as a function of cell
concentration. b Double inverse plot. By extrapolating a fitted straight
line to its intercept with the ordinate, the fraction of immunoreactive
antibody is determined as the inverse of the intercept value (1/
1.181=0.847)
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have been used to modify antibodies in order to get
antibody-chelator immunoconjugates. In our study, ritux-
imab was modified via thiourea bonds formed between ε-
NH2 groups of lysine residues on the antibody molecule
and the isothiocyanate-benzyl-DOTA (Scheme 1). Using a
pH of 9.0 for the coupling reaction and rituximab at a
concentration of 10 mg/ml resulted in a conjugate with an
approximate ratio of one DOTA molecule to one rituximab
molecule, which was considered not to be sufficient for
prompt labelling with the needed amount of radiometal (e.g.
1,480–3,700 MBq per 5 mg of antibody), for example 177Lu.
Increasing the pH from 9.0 to 9.5, and the concentration of
antibody from 10 mg/ml to 100 mg/ml resulted in a
conjugate with multiple DOTA molecules per antibody
molecule [(DOTA)4-rituximab]. Comparing the (DOTA)4-
rituximab immunoconjugate with commercially available
rituximab, no significant influence of conjugation on the
immunoreactivity with cells of the lymphoma cell line L-
VB1 was found by FACS assay. This indicates strong
binding of (DOTA)4-rituximab to the CD20-expressing
target cells and also indicates that rituximab is very robust
even under reaction conditions of pH 9.5. However, when
the ratio of DOTA molecules to antibody molecules was
increased to 8:1 [(DOTA)8-rituximab], the immunoreactiv-
ity was drastically reduced (50%), which indicates that
conjugation of eight DOTA molecules per rituximab
molecule affects the binding sites of the antibody. There-
fore, the (DOTA)4-rituximab conjugate in kit form appears
to be suitable for use in radioimmunotherapy, whereas in
the (DOTA)8-rituximab conjugate most of the immunore-
activity of the antibody is lost and this conjugate cannot be
used in patients. Rituximab is a very robust antibody with
regard to chemical modification, since up to four chelator
molecules per antibody molecule did not result in a
significant loss of immunoreactivity.
The most suitable radionuclide for radioimmunotherapy
is not defined yet. 131I is not an ideal radionuclide, mainly
because of radiation protection issues. Recently, special
attention has been paid to 177Lu. 177Lu has the advantage
that besides its relatively low-energy β-emission a small
amount of γ-radiation (113 keV 6.5%; 208 keV 11%),
making it suitable for scintigraphic imaging, is emitted as
well. This allows localization of the radiolabelled antibody
conjugates in vivo and dosimetry to be performed. The
labelling of (DOTA)4-rituximab in a kit formulation with
177Lu was straightforward (less than 20 min) and sufficient
(1,480 MBq per 5 mg in a kit), making the product suitable
for routine clinical use. 177Lu appears to be ideal because of
its low-energy β-emission. The low-energy β-emission
makes it particularly suitable for imaging small or diffusely
infiltrating tumours which are often found in NHL patients,
since a lower energy β-emission results in a more
favourable tumour to non-tumour ratio than higher energy
β-emission [19, 20]. For example, the energy of the 90Y β-
radiation might be too high for these tumours. In
calculations and measurements with human phantoms,
Song et al. found that 131I is superior to 90Y, especially
for tumours smaller than 2 cm [21].
Nevertheless, 90Y was also evaluated for its radio-
labelling efficiency in our study for possible use in patients
with distinct bulky disease. In such patients, the use of a
radionuclide “cocktail” might be optimal. 90Y is a pure β-
emitting high-energy radiometal. Compared to 131I, 90Y has
a longer β-energy path and can thus deliver more energy to
tumours (90Y, 2.3 MeV; 131I, 0.6 MeV), while it has a
shorter half-life (2.7 days) and lack of γ-radiation, which
anyway does not contribute to any therapeutic effect [13].
However, the labelling yield achieved with our (DOTA)4-
rituximab kit, reconstituted with water, was not sufficient
with 90Y, which may have been due to the low pH range
(5.5–6.0) under these conditions. We therefore adjusted the
pH of the kit to the range 7.0–7.8 by reconstitution with
0.25 M ammonium acetate buffer, pH 8.8. At this pH, 5 mg
of (DOTA)4-rituximab was successfully labelled with
925 MBq of 90Y within 30 min. This indicates that the
90Y chelation rate is more pH-dependent than the 177Lu
chelation rate.
The stability of the 177Lu-DOTA-rituximab immunocon-
jugate was tested against a 105 excess of DTPA. HPLC
showed that the radiolabelled immunoconjugate was stable
for 7 days, which means that no free radiometal was
detected. Thus DOTA-rituximab is capable of stably
chelating 177Lu, which is mandatory for using 177Lu-
radiolabelled rituximab for therapy in NHL patients.
Another prerequisite for the radiolabelled rituximab
antibody for in vivo targeting is high binding affinity of
the immunoconjugated and labelled rituximab to the CD20
antigen. An assay estimating immunoreactivity, designedScheme 1 The production of DOTA-benzyl-rituximab
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by Lindmo et al. [16], was performed to determine the
immunoreactive fraction of the radiolabelled antibody.
Effective systemic targeting of CD20-positive tumour cells
was achieved with radiolabelled rituximab as illustrated in
Fig. 6a, which shows that about 80% of the radiolabelled
antibody was immunoreactive at the highest cell concen-
tration. According to the law of mass action [16], a double
inverse plot of TA/SB as a function of the inverse of cell
concentration (1/[cells]) will yield a linear relationship
based upon the assumption that the binding reaction reaches
equilibrium. The immunoreactive fraction of the radio-
labelled antibody can be determined from the intercept
value obtained by linear extrapolation to the y-axis. Our
result demonstrated such a linear relationship, described by
the equation y = 0.066x + 1.181, where y represents the
inverse SB/TA and x represents the inverse cell concentra-
tion (1/[cells]). Thus the immunoreactive fraction is
determined as r = 1/1.181 = 0.847, which also indicates
that most of the radiolabelled antibody is immunoreactive,
possessing a high binding affinity for the CD20 antigen of
lymphoma cells.
The above properties are strong indications for using this
radiolabelled DOTA4-rituximab immunoconjugate for in
vivo studies and therapy in NHL patients. Dosimetry with
177Lu-DOTA-rituximab in two patients in a therapeutic
setting demonstrated effective delivery of radiation
absorbed dose to the tumours by specific binding of the
antibody to the tumours. The results of the dosimetry for
the red marrow compare very well with the data reported by
Scheidhauer et al. [18] who used iodinated rituximab.
However, the whole-body dose appeared to be somewhat
lower with our compound (0.25 mGy/MBq in our study vs.
0.37 mGy/MBq in the study with the iodinated rituximab).
On the other hand, the doses for Zevalin (0.65 mGy/MBq
for the red marrow and 0.54 mGy/MBq for the whole body)
are clearly higher than ours [22]. This is related to the
higher energy of 90Y compared to 177Lu. This becomes
evident when comparing the effective half-life of the
radiolabelled antibody. We found an effective half-life of
132 h, but the half-life of Zevalin has been found to be only
27 h [23]. Besides the shorter physical half-life of 90Y
compared to 177Lu, the difference in effective half-life also
appears to be related to the different antibodies. The use of
a chimeric antibody results in a slower clearance.
In summary, this is the first report of stable binding of a
sufficient activity of 177Lu to rituximab as well as the first
report of the dosimetry of this novel radioimmunoconjugate
in patients. The evaluation of 177Lu-DOTA-rituximab in a
phase I/II clinical trial is in progress. However, the results
of other studies using radiolabelled antibodies in NHL
patients are very encouraging. Higher remission rates as
well as longer lasting remissions could be achieved than
with, for example, rituximab alone. Additionally, we
showed that radioimmunotherapy can still be effective in
patients who no longer respond to rituximab [22]. Further
clinical trials should seek to determine at what time point in
the course of the disease should radioimmunotherapy be
given. The first results in a larger group of patients has
indicated that it might be beneficial to use radiolabelled
antibodies early [11]. However, these results need to be
confirmed by other groups.
Conclusion
A DOTA4-rituximab kit formulation was developed in this
study, in which multiple DOTA molecules are conjugated to
a rituximab antibody. The (DOTA)4-rituximab kit is
suitable for labelling with 177Lu or 90Y, and immunoreac-
tivity is retained before and after labelling with the
radiometal. Good uptake of the immunoconjugate was seen
in two NHL patients. This (DOTA)4-rituximab kit can
produce high specific activity 177Lu- and/or 90Y-labelled
antibody for clinical studies.
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